TSH Biopharm Corporation Limited (TPEX:8432)

Market Cap	1.97B +8.7%
Revenue (ttm)	1.34B +11.1%
Net Income	147.56M +43.9%
EPS	3.83 +43.4%
Shares Out	38.40M
PE Ratio	13.40
Forward PE	n/a
Dividend	2.61 (5.09%)
Ex-Dividend Date	Jun 16, 2025

Volume	25,030
Average Volume	36,253
Open	51.10
Previous Close	50.80
Day's Range	50.70 - 51.40
52-Week Range	45.90 - 59.30
Beta	0.33
RSI	51.56
Earnings Date	Aug 3, 2026

About TSH Biopharm Corporation

TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid biopsy test designed for MRD detection and surveillance in stage I-III solid tumor patients; AlphaLiquid 100, a liquid biopsy test designed for patient...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 76
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 8432

Financial Performance

In 2025, TSH Biopharm Corporation's revenue was 1.34 billion, an increase of 19.79% compared to the previous year's 1.12 billion. Earnings were 139.26 million, an increase of 23.14%.